SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration
Lung cancer
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls
The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.
April 21, 2026
 · 
2 min read
 · 
Tristan Manalac
Team of businesspeople in paper ship finding the way forward. Manager and team leader concept, vector illustration.
Opinion
As Duchenne innovation booms, let’s ensure it becomes real progress
At Sarepta Therapeutics, we’ve seen it all. Here are the questions I believe we should be asking to move forward in Duchenne muscular dystrophy.
April 21, 2026
 · 
7 min read
 · 
Louise Rodino-Klapac
Close up of a pile of cardboard boxes. They have been stamped "Defective Product" and "Product Recalled". The boxes are bathed in soft yellow neutral lighting.
Manufacturing
Viatris recalls extended-release Xanax over dissolution test failure
Viatris, which Pfizer created in 2020, voluntarily withdrew extended-release products made at a plant in Ireland after an analysis revealed an issue that could affect bioavailability.
April 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Balloons in the cloudy sky paper cutting art Sky background clouds, scene 3D illustration
Venture capital
Biotech has become a good news story. Let the sun shine
Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech entrepreneurs have BioSpace Senior Editor Annalee Armstrong feeling upbeat about the biotech scene.
April 20, 2026
 · 
2 min read
 · 
Annalee Armstrong
Risograph Shopping Cart with geometric shapes. Objects in trendy riso graph print texture style design with geometry elements.
Mergers & acquisitions
Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal
After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and its gene delivery technology.
April 20, 2026
 · 
2 min read
 · 
Annalee Armstrong
Lost at sea strategic crisis and strategy trouble concept as a target floating aimlessly in an ocean of confused blue darts as a business metaphor for economic or corporate plan despair as a 3D illustration.
Cell therapy
Agenus cancer cocktail records 0% response rate, missing midstage goal
An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers Agenus and MiNK Therapeutics aren’t giving up on the program just yet.
April 20, 2026
 · 
2 min read
 · 
Gabrielle Masson
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Sickle cell disease
Novo’s late-stage sickle cell win piles pressure on competitors
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.
April 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Two boxing gloves give a fist bump on a colored background. Collage art
Lung cancer
Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.
April 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Reaching an agreement. Businessmen shake hands and make a deal. vector
Mergers & acquisitions
UCB elevates epilepsy expertise with up to $1.15B Neurona takeover
The acquisition of Neurona will put UCB in both the epilepsy and cell therapy space, even as many of its fellow pharmas move away from the latter modality.
April 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS